HROWM Company Profile and Key Details

HROWM has shown mixed momentum, losing -0.73% over the past week and -2.93% over the past quarter, though year-to-date performance is down -2.93%.

Harrow Health, Inc. 11.875% Senior Notes due 2027 earnings surprise history is a mixed track record. The quarter that ended August 11, 2025, missed forecasts by 1603.31%. The prior quarter beat by 978.87%. Over the last six quarters, Apple has recorded several small beats. These include 75.83% in March 30, 2024.

Harrow Health, Inc. 11.875% Senior Notes due 2027 last paid a dividend of 2.23 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$22.03. This means the shares are trading below this model’s fair value.

Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ:HROWM) closed at $26.03 USD, losing -$0.02 (-0.08%) from the previous close of $26.05. The stock is currently within 5% of its 52-week low $24.90 and $27.70. With a market capitalization of about $1.34 billion, Harrow Health, Inc. 11.875% Senior Notes due 2027 is classified as a small-cap and shows lower-than-market volatility (beta ~0.14). Key stats such as the average daily volume over the past year has been around 10.55 thousand shares, trading with heavier-than-usual volume. Headquartered in Nashville, None, Harrow Health, Inc. 11.875% Senior Notes due 2027 operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO Mark L. Baum, the company employs approximately 217 people and listed since December 29, 2022. Harrow, Inc. engages in the development, production, and sale of innovative medications.

Our AI price prediction model suggests that Harrow Health, Inc. 11.875% Senior Notes due 2027 stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.19%, with price expected at $25.46 by November 24, 2023, within a range of $25.18 to $25.73

Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ:HROWM) shares are flat -2.93% year-to-date Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Harrow Health, Inc. 11.875% Senior Notes due 2027 trading at a premium to the broader market with a P/E of -401.13.

Harrow Health, Inc. 11.875% Senior Notes due 2027 trades at a P/E ratio of -401.13, slightly below the S&P 500 average, with a price-to-sales ratio of 7.98 and a price-to-book ratio of 42.56 reflecting a rich premium to book value. The P/FCF stands at -97.44, also below market averages. Compared to sector medians, Harrow Health, Inc. 11.875% Senior Notes due 2027 P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.